Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.
Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Solid Value Pick in Pharmaceuticals NOVARTIS AG (
NYSE:NVS ) offers strong profitability, solid financial health, and an attractive valuation, making it a potential value pick in the pharmaceuticals sector.
Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks IEQ inherits the portfolio DNA of its mutual fund ancestor, now in the tax-efficient wrapper increasingly favored by investors.
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting its near-term impact on pharma stocks.
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion.
